Humacyte is trading 6% up at $0.58, and broader growth-stock demand and pre-Fed positioning may be supporting shares.
- Broader biotech sector is down 2.11%.
- No new company-specific announcement explaining the September 16, 2026 move was identified.
- Humacyte’s scheduled H.C. Wainwright investor presentation occurred at 11:00 a.m. ET.